There are hundreds of thousands of human samples currently stored in the UK; the research questions they could address are endless. It has been well documented that human samples are excellent experimental models; their use early in drug development can decrease the risk of failed progression into Phase I and II trials.  

As a relatively new means of conducting research in the life sciences, RWE, or real-world evidence, is data that comes from “real world settings” such as a clinical practice. Studies driven by real world evidence, or real-world data (RWD), can utilize data from medical records or claims databases, be conducted prospectively in observational studies or adhere to a mixed, hybrid-design approach.

Antibodies have re-shaped biomedical researches since their discovery. From research tools to therapeutics and diagnostics, antibodies are indispensable in finding cures for a host of different diseases. In recent years, antibody-based therapeutics have dramatically changed the way we treat diseases, especially in oncology. The recent introduction of platforms has further advanced how antibodies are being used.

Stem cells have attracted a great deal of deserved attention due to their lineage-independent characteristics. In other words, they have the potential to be differentiated into a countless number of cell types. Adult stem cells, otherwise known as inducible pluripotent stem cells (iPSCs), are particularly favorable as research tools because they are derived from a patient’s somatic cells such as blood, skin or muscle.

As a relatively new means of conducting research in the life sciences, RWE, or real-world evidence, is data that comes from “real world settings” such as a clinical practice. Studies driven by real world evidence, or real-world data (RWD), can utilize data from medical records or claims databases, be conducted prospectively in observational studies or adhere to a mixed, hybrid-design approach.